Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

2 Health Care And Biotech ETFs Poised For Robust Returns This Year

By Investing.com (Tezcan Gecgil/Investing.com )ETFsJun 09, 2022 08:07
uk.investing.com/analysis/2-health-care-and-biotech-etfs-poised-for-robust-returns-this-year-200521986
2 Health Care And Biotech ETFs Poised For Robust Returns This Year
By Investing.com (Tezcan Gecgil/Investing.com )   |  Jun 09, 2022 08:07
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously during the past 2 years.

However, with the easing of global coronavirus restrictions, along with a broad market selloff, the fortunes of these companies changed entirely in 2022.

For example, the Dow Jones Health Care Index is down about 9.4% year-to-date—while still returning 3.5% over the past 12 months. On the other hand, the NASDAQ Biotechnology Index has dropped over 20.6% year-to-date (YTD) and 24.8% in the past 52 weeks, meaning it is now in the bear market territory.

In comparison, the S&P 500 and the NASDAQ 100 have lost 13.6% and 22.7% so far in 2022.

Still, these declines potentially offer better entry points into many robust stocks and exchange-traded funds (ETFs) that hold them. So, today's article introduces two ETFs that deserve readers' attention during the rest of the year.

1. Invesco S&P 500 Equal Weight Health Care ETF

  • Current Price: $280.86
  • 52-week range: $267.79 - $322.92
  • 52-week range: 0.65%
  • Expense ratio: 0.40% per year

Health care stocks are typically excellent defensive plays in an environment of high inflation and market volatility. In addition, metrics suggest these companies could further benefit from changing demographics stateside.

For instance, the most recent census shows that America is aging. Research highlights:

"By 2030, more people in the United States will be older than age sixty-five than younger than age five. Our health care system is unprepared for the complexity of caring for a heterogeneous population of older adults."

Health care spending currently accounts for about a fifth of the national gross domestic product (GDP). As the needs of Americans change and possibly increase, we can expect health care stocks to capture part of that growth as well.

Therefore, the first fund on today's list is the Invesco S&P 500 Equal Weight Health Care ETF (NYSE:RYH). It offers exposure to large- and mid-cap health care companies from the S&P 500 index.

RYH Weekly Chart
RYH Weekly Chart

RYH currently has 66 holdings, where the top 10 comprise almost 14% of $890.2 million in net assets. The fund was first listed in November 2006.

Over a quarter of the companies are in the health care equipment & supplies segment. Next come health care providers & services (24.6%), life sciences tools & services (18.2%), pharmaceuticals (15.4%), and biotechnology (13.1%).

Among the leading names on the roster are Viatris (NASDAQ:VTRS); Catalent (NYSE:CTLT), Merck & Company (NYSE:MRK), Vertex Pharmaceuticals (NASDAQ:VRTX), Eli Lilly (NYSE:LLY), McKesson (NYSE:MCK) and Cigna (NYSE:CI).

RYH hit a 52-week on May 12 and is down close to 12.3% YTD. Trailing price-to-earnings (P/E) and price-to-book (P/B) ratios stand at 16.75x and 4.26x.

We like the diversity offered by this equal-weight ETF. Interested readers could find long-term value in RYH around these levels.

2. First Trust NYSE Arca Biotechnology Index Fund

  • Current Price: $136.53
  • 52-week range: $124.43 - $176.64
  • Dividend yield: 1.67%
  • Expense ratio: 0.55% per year

Academic research suggests:

"The biotechnology industry has been an engine of innovation for the U.S. healthcare system and, more generally, the U.S. economy. It is by far the most research-intensive industry in the U.S."

At present, the U.S. biotech industry is valued around $140 billion. A recent survey revealed a "strengthening investor appetite" for biotechs despite the recent decline in biotech shares. Among the investors surveyed, "66% think that biotech will outperform the broader market in 2022," while "58% plan to increase their exposure to the sector."

Next up on the list is the First Trust NYSE Arca Biotechnology Index Fund (NYSE:FBT). It invests in global biotech firms that concentrate on life sciences tools, genetic engineering, molecular biology, and genomics. It started trading in June 2006, and has close to $1.3 billion in net assets.

FBT Weekly Chart
FBT Weekly Chart

This passively managed ETF tracks the ARCA Biotechnology Index. It is rebalanced quarterly and holds a basket of 30 stocks.

40% of the portfolio is the top 10 stocks. Among them are United Therapeutics (NASDAQ:UTHR), Grifols (NASDAQ:GRFS), Gilead Sciences (NASDAQ:GILD), Mettler-Toledo International (NYSE:MTD), Qiagen (NYSE:QGEN), Amgen (NASDAQ:AMGN), and Seagen (NASDAQ:SGEN).

FBT is down roughly 15.7% YTD and 19% over the past 12 months. The fund saw a multi-year low also on May 12.

Trailing P/E and P/B ratios stand at 15.11x and 3.61x. Contrarian readers ready to become "greedy when others are fearful" could consider buying the dips in FBT.

2 Health Care And Biotech ETFs Poised For Robust Returns This Year
 

Related Articles

2 Health Care And Biotech ETFs Poised For Robust Returns This Year

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Rooble Axmed
Rooble Axmed Jun 09, 2022 21:50
Saved. See Saved Items.
This comment has already been saved in your Saved Items
rooble axmed maxamed warsame
Rooble Axmed
Rooble Axmed Jun 09, 2022 21:50
Saved. See Saved Items.
This comment has already been saved in your Saved Items
065 6933359
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email